These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 4272666)

  • 21. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports].
    Rosati G; Agnetti V; Mura F; Granieri E
    Minerva Med; 1974 May; 65(33):1811-23. PubMed ID: 4602058
    [No Abstract]   [Full Text] [Related]  

  • 22. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease.
    Muenter MD
    Neurology; 1970 Dec; 20(12):Suppl:6-13. PubMed ID: 4921587
    [No Abstract]   [Full Text] [Related]  

  • 23. [Preliminary impressions of the therapeutic effectiveness of L-dopa in Parkinson's disease].
    Buscaino GA; Campanella G
    Sist Nerv; 1970; 22(2):82-91. PubMed ID: 5504561
    [No Abstract]   [Full Text] [Related]  

  • 24. [Case reports of some mental disorders in parkinsonian patients treated with L-dopa].
    Almici GM; Sbarbaro V
    Minerva Med; 1974 Feb; 65(8):398-401. PubMed ID: 4820722
    [No Abstract]   [Full Text] [Related]  

  • 25. [Parkinson's syndrome. 4 years of experience in treatment with L Dopa associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; de Ajuriaguerra J
    Nouv Presse Med; 1973 Feb; 2(5):315-6. PubMed ID: 4686226
    [No Abstract]   [Full Text] [Related]  

  • 26. ["Precursor-therapy" with active amines. 2. Treatment of Parkinson's disease by L-5-HTP (L-5-hydroxytryptophan)].
    Sano I; Taniguchi K
    Seishin Shinkeigaku Zasshi; 1971; 73(11):835-9. PubMed ID: 5316906
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of L-DOPA in Parkinsonism with special reference to the study by double-blind method].
    Okajima T; Kubota A; Nakahara N; Takeda S; Shimomura K
    Naika; 1972; 29(2):335-43. PubMed ID: 4552443
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical and quantitative electroencephalographical effects of MK 940.
    Gannon P; Itil T; Keskiner A; Hsu B
    Arzneimittelforschung; 1970 Jul; 20(7):971-4. PubMed ID: 4918922
    [No Abstract]   [Full Text] [Related]  

  • 29. [Significance of transmethylation and S-adenosylmethionine (SAM) in the management of Parkinson's disease with L-dopa].
    Passeri M; Ceccato S
    Minerva Med; 1972 Apr; 63(30):1722-59. PubMed ID: 4502737
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of ergot derivative lisuride in Parkinson's disease.
    Suchy I; Horowski R
    Adv Neurol; 1984; 40():515-21. PubMed ID: 6695629
    [No Abstract]   [Full Text] [Related]  

  • 31. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients.
    Goodwin FK; Murphy DL; Brodie HK; Bunney WE
    Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729
    [No Abstract]   [Full Text] [Related]  

  • 32. Serotonergic mechanisms in Parkinson's disease.
    Chase TN
    Arch Neurol; 1972 Oct; 27(4):354-6. PubMed ID: 4262400
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 34. [L-Dopa in the treatment of Parkinson's disease. (Considerations on 51 cases)].
    Mazza C; Buffatti PF; Bazzan A; Lion P
    Fracastoro; 1970; 63(5):768-73. PubMed ID: 5519378
    [No Abstract]   [Full Text] [Related]  

  • 35. Use of drugs in the treatment of parkinsonism.
    Nutr Rev; 1970 Jan; 28(1):7-9. PubMed ID: 4906659
    [No Abstract]   [Full Text] [Related]  

  • 36. [Long-term treatment of Parkinsonism with L-dopa].
    Presthus J; Holmsen R
    Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916
    [No Abstract]   [Full Text] [Related]  

  • 37. [Efficacy and side effects of L-dopa in patients with Parkinson's syndrome].
    Lombardo L
    Arch Invest Med (Mex); 1973; 4(3):215-24. PubMed ID: 4784173
    [No Abstract]   [Full Text] [Related]  

  • 38. A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel).
    Merrick EM; Schmitt PP
    Curr Ther Res Clin Exp; 1973 Aug; 15(8):552-8. PubMed ID: 4200529
    [No Abstract]   [Full Text] [Related]  

  • 39. [Biochemistry and treatment of Parkinson's disease].
    Barbeau A
    Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
    [No Abstract]   [Full Text] [Related]  

  • 40. Psychiatric disturbances in Parkinson's disease.
    Celesia GG; Wanamaker WM
    Dis Nerv Syst; 1972 Sep; 33(9):577-83. PubMed ID: 4649149
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.